Log In
BCIQ
Print this Print this
 

BIND-014

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionPolymeric nanoparticle containing docetaxel that concentrates in the neovasculature surrounding tumors and targets prostate-specific membrane antigen (PSMA; FOLH1; GCPII)
Molecular Target Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of ActionBinds prostate-specific membrane antigen (PSMA)
Therapeutic ModalityNanotherapy: Protein-based nanoparticles

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$40.0M

$40.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/01/2016

$40.0M

$40.0M

0

Get a free BioCentury trial today